New IP Riders 2026: Should I switch to the new Enhanced IncomeShield riders?

From 1 April 2026, the existing Deluxe Care and Classic Care IP riders will no longer be available for new purchases. In their place, Income has introduced Optima Care rider and Essential Care rider – new IP riders offering lower premiums but higher co-payment. Find out if you should keep your current “grandfathered” plan or switch to the new IP riders for potential premium savings.

iFAST Insurance Team
iFAST Insurance Team 02 Apr 2026 12144 Views
New IP Riders 2026: Should I switch to the new Enhanced IncomeShield riders?

Following our previous updates on IP rider changes and the revisions to Income’s shield plans in October 2025, we are back with an update on the new Income shield riders launched on 1 April 2026.

Have a shield plan with another insurer? Read our other shield plan updates here:

Here is what’s new in April 2026:

🛡️ Main shield plan: Changes to Enhanced IncomeShield

1.      Increase in premiums

Plan Name

Enhanced IncomeShield Preferred

Enhanced IncomeShield Advantage

Enhanced IncomeShield Basic

Ward Entitlement

Private Hospital

Class A Ward in public hospitals

Class B1 Ward in public hospitals

Average Premium Adjustment

+14%

+13%

+7%

Enhanced IncomeShield plans will be repriced from 1 April 2026 affecting new purchases and renewals. Premiums will increase by an average of 14% for Enhanced IncomeShield Preferred, 13% for Enhanced IncomeShield Advantage plans, and 7% for the Enhanced IncomeShield Basic plan.

Premiums shown are retrieved on 18 March 2026 for policies issued on standard terms. For illustration purposes only.

2.      Benefit revision

The Pregnancy and Delivery-Related Complications benefit will no longer require the use of a preferred partner for an extended list of conditions. The Cell, Tissue and Gene Therapy (CTGTP) benefit has also been updated to include coverage for ancillary treatments.

🛡️Existing Integrated Shield Riders: Deluxe Care and Assist Care riders

Premiums for these existing riders will remain unchanged. Policyholders who purchased their riders between 27 November 2025 to 31 March 2026 will have to transit to the new riders by their first policy renewal after 1 April 2028.

As of 1 April 2026, these riders are no longer be available for new purchases. However, those with a Deluxe Care or Classic Care rider can switch to the new Income IP riders between 1 April 2026 and 31 March 2028 without additional underwriting. This rider switch is irreversible.  

🛡️New Integrated Shield Riders: Optima Care rider and Essential Care rider

1.     Optima Care Rider

Introduced on 1 April 2026, here are the key changes for the new Optima Care rider:

  • Co-payment and Deductible

[Existing] Deluxe Care rider

[New] Optima Care Rider

Co-payment for Panel providers

5% co-payment required for up to $3,000 each policy year

5% co-payment up to $6,000 each policy year.

Co-payment for Extended panel providers

5% co-payment required for up to $3,000 each policy year

An additional extended panel and non-panel payment of up to $2,000 will be required for extended panel treatments.

8% co-payment up to $6,000 each policy year.

Extended panel and non-panel payment no longer required.

Co-payment for Non-panel providers

5% co-payment with no limit on the co-payment required.

An additional extended panel and non-panel payment of up to $2,000 will be required for non-panel treatments.

8% co-payment with no limit on the co-payment required.

Extended panel and non-panel payment no longer required.

Annual Deductible

Not required

Required based on the policy terms and selected ward.

One key difference between Optima Care rider and Deluxe Care rider is the co-payment required. While the new Optima Care rider maintains a 5% co-payment for panel providers, this increases to 8% co-payment for extended panel and non-panel providers. The co-payment cap will also increase from $3,000 to $6,000 for the new Optima Care rider. Under the new Optima Care rider, you will also have to pay for the annual deductible required from your policy.

The new Optima Care rider will remove the required additional extended panel and non-panel payment (ENP).

  • Benefits

The Optima Care rider also introduces several enhanced benefits, including extended pre- and post-hospitalisation coverage (additional 80 days before admission and after discharge for panel treatment under the Enhanced Advantage plan, and additional 80 days post-discharge for the Enhanced Preferred plan). It also introduces coverage for Cell, Tissue and Gene Therapy (CTGTP) treatments not on MOH’s CTGTP list, as well as juvenile benefits for insureds under 18, such as a one-time autism testing benefit and a critical care payout. There is no change to the cancer drug limits benefit when compared to the Deluxe Care rider.

  • Premiums

The new Optima Care Rider offers up to 54% lower premiums when compared to the Deluxe Care rider. The biggest premium saving is seen when Optima Care rider is attached to Enhanced IncomeShield Advantage or Basic plans, with premium savings averaging 46%.

Premiums shown are retrieved on 18 March 2026 for policies issued on standard terms. For illustration purposes only.

2.     Essential Care Rider

Introduced on 1 April 2026, here are the key changes for the new Essential Care rider:

  • Co-payment

[Existing] Classic Care rider

[New] Essential Care Rider

Co-payment for Panel providers

10% co-payment up to $3,000 each policy year.

7% co-payment up to $6,000 each policy year.

Co-payment for Extended panel providers

10% co-payment up to $3,000 each policy year.

An additional extended panel and non-panel payment of up to $2,000 will be required for extended panel treatments.

10% co-payment up to $6,000 each policy year.

Extended panel and non-panel payment no longer required.

Co-payment for Non-panel providers

10% co-payment with no limit on the co-payment required.

An additional extended panel and non-panel payment of up to $2,000 will be required for non-panel treatments.

10% co-payment with no limit on the co-payment required.

Extended panel and non-panel payment no longer required.

Annual Deductible

Not required

Required based on the policy terms and selected ward.

Similar to the Deluxe-to-Optima transition, moving from the Classic Care Rider to the Essential Care Rider means accepting a higher annual co-payment limit ($6,000 vs. $3,000). However, the Essential Care Rider rewards you for using Panel doctors by dropping the base co-payment rate to 7% (down from the Classic Care's flat 10%). Co-payment for extended and non-panel providers will remain at 10%.

Under the new Essential Care rider, you will have to pay for the annual deductible required from your policy. However, the additional extended panel and non-panel payment (up to $2,000) will no longer apply.

  • Benefit

Essential Care rider introduces coverage for Cell, Tissue and Gene Therapy (CTGTP) treatments not on MOH’s CTGTP list. There is no change to the cancer drug limits benefit when compared to the Classic Care rider.

  • Premiums

The largest premium savings are seen when the Essential Care rider is attached to Enhanced IncomeShield Advantage or Basic plans with premium savings averaging 49%.

Premiums shown are retrieved on 18 March 2026 for policies issued on standard terms. For illustration purposes only.

Should I make the switch to the new Income IP riders? This is what we think.

1.     I have a Deluxe Care Rider, should I switch to Optima Care Rider?

The Optima Care rider offers additional benefits not in Deluxe Care rider. This includes extended pre- and post-hospitalisation coverage, coverage for CTGTP treatments not on MOH’s list, and juvenile benefits for insureds under 18, including a one-time autism test and critical care payout.

However, the new Optima Care rider requires an annual deductible, resulting in consistently higher out-of-pocket costs compared to the Deluxe Care rider.

Our recommendation: Stay on Deluxe Care Rider

Annual deductibles range from $1,500 to $3,500. Under the Deluxe Care rider, out-of-pocket costs are capped at $3,000 for panel providers and $5,000 for Extended Panel providers. In comparison, the new Optima Care rider may result in out-of-pocket costs of up to $9,500.

While switching to Optima Care rider offers average premium savings of 23% (Preferred plan) and 46% (Advantage or Basic plans), the absolute savings are relatively modest. For example, a 65-year-old can save 45% of premiums (around $600 annually) by switching from Deluxe Care to Optima Care rider. However, in the event of a hospitalisation in a Class A ward or private hospital, the maximum out-of-pocket cost could increase from $3,000 to $9,500  (assuming treatment by a panel specialist).

Given the significantly higher financial exposure, we recommend retaining the Deluxe Care rider for better protection against large hospital bills.

2.     Should I switch from my Classic Care Rider to Essential Care Rider?

The Essential Care rider introduces a lower 7% co-payment for panel treatments (down from a flat 10%). However, this reduction in co-payment does little with the co-payment cap increasing to $6,000 and the annual deductible now required.

Essential Care rider also offers significantly reduced premiums, with an average of 49% savings for those on public hospital Class A or B1 ward plans (Enhanced IncomeShield Advantage or Basic). For private hospital plan holders (Enhanced IncomeShield Preferred), switching to Essential Care provides an average 24% savings on the rider.

Our recommendation:

  • Private hospital users (Enhanced IncomeShield Preferred): Stay on Classic Care Rider

While premiums are lower for the new Essential Care rider, it offers limited additional benefits when compared to the Classic Care rider. Its main enhancements are coverage for non-MOH listed CTGTP and a reduced 7% co-payment when using panel providers. However, this offers limited practical value due to the higher $6,000 co-payment cap and the introduction of an annual deductible.

Although switching to the Essential Care rider yields an average premium saving of 24%, the absolute savings are typically lower than the additional $3,000 co-payment required. Given the higher cost of private hospital bills, retaining the lower out-of-pocket cap under the Classic Care rider remains the safer financial choice for now.

  • Public hospital users (Enhanced IncomeShield Advantage or Basic): Consider carefully

Premiums are significantly lower for public hospital plans, offering an average 49% savings for those on public hospital Class A or B1 ward plans (Enhanced IncomeShield Advantage or Basic). As public hospital bills are generally lower, the risk of hitting the $9,500 maximum out-of-pocket limit may be lower.

However, policyholders should weigh these savings against the higher out-of-pocket risk and ensure they are comfortable with the trade-off before switching to the Essential Care rider.

Is your Integrated Shield Plan (IP) still keeping up with your needs?

Don’t just review your coverage, get rewarded for it. From now till 30 June 2026, review your Integrated Shield Plan (IP) and rider with us and enjoy up to $50 Cash Reward plus up to 45% commission rebates.

No Agent? No Problem! Transfer your Income or Raffles plan to us and get a $5 Reward. Click here to get started.

*Terms and conditions apply. Read more here.

Unsure about what to do with your Income Shield plan?

Click here to schedule a complimentary review

You may also be interested in:

Available Products on FSMOne Insurance

Term Life, Whole Life, Critical Illness, Annuity, Health, Endowment, General Insurance (Personal and Commercial)

from AIA, AIG, Allianz, China Taiping, Cigna, Chubb, Etiqa Insurance, FWD Insurance, Great Eastern, Henner, Income, Manulife, MSIG, Raffles Health Insurance, Singlife, Sompo, Tokio Marine, and QBE.

*Please check with our team if the product you want is available on FSMOne Insurance

Disclaimer:
All materials and content found in this advertisement are strictly for information purposes only and should not be considered as an offer or solicitation to transact in any product. This advertisement is not a contract of insurance.
Insurance products are underwritten by the respective insurance partners and distributed by iFAST Financial Pte Ltd (“iFAST”). You are advised to review the specific terms, conditions and exclusions in the relevant policy contract.
You are advised to read the key product documents, including (but not limited to) the product summary, before deciding whether the product is suitable for you. You should consider carefully if the products you are purchasing are suitable for your financial objectives, experience, risk tolerance and other personal circumstances. If you are uncertain about the suitability of a product, please seek advice from a financial adviser before making a decision to purchase the product.
While iFAST and its third-party providers strive to provide accurate and timely information, there may be inadvertent omissions, inaccuracies, and typographical errors. Opinions expressed herein are subjected to change without notice.
The comparisons and opinions provided are based on publicly available data/information and are intended to provide a general overview of the insurance products discussed. These comparisons do not cover all available products and may not fully illustrate every aspect of the products discussed.
Purchasing a life insurance policy is a long-term commitment, and early termination may involve significant costs. The surrender value, if any, may be zero or less than the total premiums paid.
This advertisement has not been reviewed by the Monetary Authority of Singapore.

All materials and contents found in this site are strictly for general circulation and informational purposes only and should not be considered as an offer, or solicitation, to deal in any of the funds or products found/identified in this site. While iFAST Financial Pte Ltd ("IFPL") has tried to provide accurate and timely information, there may be inadvertent delays, omissions, technical or factual inaccuracies and typographical errors. Any opinion or estimate contained in this report is made on a general basis and neither IFPL nor any of its servants or agents have given any consideration to nor have they or any of them made any investigation of the investment objective, financial situation or particular need of any user or reader, any specific person or group of persons. You should consider carefully if the products you are going to purchase are suitable for your investment objective, investment experience, risk tolerance and other personal circumstances. If you are uncertain about the suitability of the investment product, please seek advice from a financial adviser, before making a decision to purchase the investment product. Past performance is not indicative of future performance. The value of the investment products and the income from them may fall as well as rise. Opinions expressed herein are subject to change without notice. In respect of any matters arising from, or in connection with the said research analyses or research reports, recipients of the report are to contact IFPL at 10 Collyer Quay, #26-01 Ocean Financial Centre Building, Singapore 049315, or by telephone at +65 6557 2853. Where the report contains research analyses or research reports from a foreign research house and if the recipient of such research analyses or research reports is not an accredited investor, expert investor, institutional investor or an ex-accredited investor, IFPL accepts legal responsibility for the contents of such analyses or reports to such persons only to the extent as required by law. Please note that only certain security(ies) herein are available to all investors, while the rest are only available for certain persons to invest in, such as Accredited Investors (as defined in the Securities and Futures Act) or one who invests at least S$200,000 (or its equivalent currency) per transaction. To qualify as an Accredited Investor, one needs to submit a declaration form and certain relevant supporting documents, according to iFAST’s prevailing policies and procedures.

Please read our full disclaimers on the website at ( https://secure.fundsupermart.com/fsmone/policies/328125/investment-account-terms-&-conditions).

iFAST Financial Pte Ltd (IFPL) (registered address: 10 Collyer Quay #26-01 Ocean Financial Centre Singapore 049315, Telephone: 6557 2000) holds the Financial Advisers Licence issued by the Monetary Authority of Singapore ('MAS') to conduct regulated activities of advising on securities, marketing of collective investment schemes and arranging of any contract of insurance in respect of life policies, other than a contract of reinsurance and the Capital Markets Services Licence issued by the MAS to conduct regulated activities of dealing in securities and providing custodial services for securities. While IFPL has made every effort to ensure the independence of the report's contents, IFPL's nature of business is such that IFPL and its connected and associated entities together with their respective directors, officers and staff may be involved in providing dealing or investment-related services in the abovementioned securities, and have taken or may take positions in the securities mentioned in this report, and may also act as the principal for any buy or sell trades.